Tag: Benzoxazine ampakine

  • CX-546

    Benzoxazine ampakine

    A second-generation Cortex Pharmaceuticals ampakine with improved AMPA receptor modulation kinetics and reduced respiratory depression liability.

    Abstract

    CX-546 (1-(1,4-benzodioxan-6-ylcarbonyl)piperidine; CAS 215923-54-9; molecular formula C14H17NO3; molecular weight 247.29) is a second-generation Cortex Pharmaceuticals ampakine in the benzoxazine subclass. The compound shows improved AMPA receptor modulation kinetics relative to CX-516, with deeper potentiation per binding event and longer-lasting effect. CX-546 was advanced through preclinical development for cognitive impairment and respiratory disorders (the AMPA potentiation can reverse opioid-induced respiratory depression in animal models). The compound did not advance through pivotal human trials in any indication. Pharmacokinetics: short plasma half-life (2 to 3 hours), oral bioavailability moderate. The compound is sold as a research chemical in jurisdictions where it is not scheduled.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • CX-614

    Benzoxazine ampakine

    A potent benzoxazine ampakine with research applications in BDNF upregulation and synaptic plasticity studies.

    Abstract

    CX-614 (2H,3H,6aH-pyrrolidino-[2,1-3′,2′]1,3-oxazino-[6′,5′-5,4]benzo[e]1,4-dioxan-10-one; CAS 215923-55-0; molecular formula C16H17NO4; molecular weight 287.32) is a potent benzoxazine-class ampakine developed at Cortex Pharmaceuticals as part of the same program that produced CX-516 and CX-546. CX-614 shows substantially higher AMPA potentiation potency than CX-516 in cellular assays (approximately 100-fold greater per molecule). The compound has been used extensively as a research probe for BDNF upregulation studies; chronic ampakine treatment elevates hippocampal BDNF expression through transcriptional mechanisms downstream of AMPA potentiation, providing a pharmacological model for neurotrophin-mediated synaptic plasticity. CX-614 has not been advanced to human clinical trials. The compound is sold as a research chemical with limited availability.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.